Pricing Log in Create free account
Friday 6 November 2026 Export BEAM’s income statement to Excel — free account

Beam Therapeutics Inc.

BEAM Healthcare Biotechnology

Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.

Revenue
−96.8%
EPS
−16.7%
Free cash flow
−29.5%

Quarter to September 2026, against a year earlier

26.37 0.50 +1.93%
Market cap
$2.7B
P/E
0.0×
Fwd P/E
−6.2×
Dividend yield
—
F-score
4/9
Altman Z
5.41
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Beam Therapeutics Inc. (BEAM) P/E ratio

Alert me on P/E ratio

Beam Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
26 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
NAMS NewAmsterdam Pharma Company N.V. compare n/m
VRDN Viridian Therapeutics, Inc. compare n/m
MBX MBX Biosciences, Inc. compare n/m
IDYA IDEAYA Biosciences, Inc. compare n/m
BEAM Beam Therapeutics Inc. n/m
RCUS Arcus Biosciences, Inc. compare n/m
XNCR Xencor, Inc. compare n/m
ZLAB Zai Lab Limited Unsponsored ADR compare n/m
TLX Telix Pharmaceuticals Limited compare —
Biotechnology industry median 10.3×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on BEAM